Giovanni Cimmino1, Roberta Tarallo2, Stefano Conte1, Andrea Morello3, Grazia Pellegrino3, Francesco S Loffredo4, Gaetano Calì5, Nicola De Luca3, Paolo Golino1, Bruno Trimarco3, Plinio Cirillo6. 1. Department of Cardiothoracic and Respiratory Sciences, Section of Cardiology, University of Campania "Luigi Vanvitelli", Naples, Italy. 2. Laboratory of Molecular Medicine and Genomics, Department of Medicine, Surgery and Dentistry "Schola Medica Salernitana", University of Salerno, Baronissi, SA, Italy. 3. Department of Advanced Biomedical Sciences, Division of Cardiology, University of Naples "Federico II", Naples, Italy. 4. Molecular Cardiology, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy; Cardiovascular Department, Ospedale Riuniti and University of Trieste, Trieste, Italy. 5. Department of Molecular Medicine, Medical Biotechnologies University "Federico II", Naples, Italy; Endocrinology and Experimental Oncology Institute, CNR, Naples, Italy. 6. Department of Advanced Biomedical Sciences, Division of Cardiology, University of Naples "Federico II", Naples, Italy. Electronic address: pcirillo@unina.it.
Abstract
INTRODUCTION: Platelets activation/aggregation with subsequent thrombus formation is the main event in the pathophysiology of acute coronary syndrome. Once activated, platelets show an extensive cytoskeleton rearrangement that leads to recruitment of additional platelets to finally cause haemostatic plug formation. Thus, the cytoskeleton plays a pivotal role in this phenomenon. Colchicine (COLC) is an anti-inflammatory drug proven to reduce major cardiovascular events in patients with coronary artery disease. The molecular mechanisms by which COLC exerts these protective effects remain partially still unknown. Since COLC causes disruption of tubulin, a component of cell cytoskeleton, we investigated whether this drug might interfere with platelet aggregation by acting on cytoskeleton rearrangement. METHODS AND RESULTS: Platelets isolated from healthy volunteers were activated with Adenosine Diphosphate (ADP, 20 μM) Collagen (COLL, 60 μg/ml) and Thrombin Activating Receptor Peptide (TRAP 25 μM) with/without COLC 10 μM pretreatment. After stimulus, aggregation was measured by light aggregometry overtime. Microtubules structure was assessed by immunohistochemistry and key proteins involved in regulation of actin-filament assembly and contractility such as Myosin Phosphatase Targeting subunit (MYPT), LIM domain kinase 1(LIMK1) and cofilin were evaluated by Western Blot analysis. Colchicine pretreatment significantly blunted ADP/COLL/TRAP-induced platelet aggregation (up to 40%). COLC effects appeared mediated by microtubules depolymerization and cytoskeleton disarrangement associated to inactivation of MYPT and LIMK1 that finally interfered with cofilin activity. CONCLUSIONS: Our data indicate that colchicine exerts anti-platelet effects in vitro via inhibition of key proteins involved in cytoskeleton rearrangement, suggesting that its beneficial cardiovascular properties may be due, at least in part, to an inhibitory effect of platelet activity.
INTRODUCTION: Platelets activation/aggregation with subsequent thrombus formation is the main event in the pathophysiology of acute coronary syndrome. Once activated, platelets show an extensive cytoskeleton rearrangement that leads to recruitment of additional platelets to finally cause haemostatic plug formation. Thus, the cytoskeleton plays a pivotal role in this phenomenon. Colchicine (COLC) is an anti-inflammatory drug proven to reduce major cardiovascular events in patients with coronary artery disease. The molecular mechanisms by which COLC exerts these protective effects remain partially still unknown. Since COLC causes disruption of tubulin, a component of cell cytoskeleton, we investigated whether this drug might interfere with platelet aggregation by acting on cytoskeleton rearrangement. METHODS AND RESULTS: Platelets isolated from healthy volunteers were activated with Adenosine Diphosphate (ADP, 20 μM) Collagen (COLL, 60 μg/ml) and Thrombin Activating Receptor Peptide (TRAP 25 μM) with/without COLC 10 μM pretreatment. After stimulus, aggregation was measured by light aggregometry overtime. Microtubules structure was assessed by immunohistochemistry and key proteins involved in regulation of actin-filament assembly and contractility such as Myosin Phosphatase Targeting subunit (MYPT), LIM domain kinase 1(LIMK1) and cofilin were evaluated by Western Blot analysis. Colchicine pretreatment significantly blunted ADP/COLL/TRAP-induced platelet aggregation (up to 40%). COLC effects appeared mediated by microtubules depolymerization and cytoskeleton disarrangement associated to inactivation of MYPT and LIMK1 that finally interfered with cofilin activity. CONCLUSIONS: Our data indicate that colchicine exerts anti-platelet effects in vitro via inhibition of key proteins involved in cytoskeleton rearrangement, suggesting that its beneficial cardiovascular properties may be due, at least in part, to an inhibitory effect of platelet activity.
Authors: Alberto Cecconi; Jean Paul Vilchez-Tschischke; Jesus Mateo; Javier Sanchez-Gonzalez; Samuel España; Rodrigo Fernandez-Jimenez; Beatriz Lopez-Melgar; Leticia Fernández Friera; Gonzalo J López-Martín; Valentin Fuster; Jesus Ruiz-Cabello; Borja Ibañez Journal: J Cardiovasc Transl Res Date: 2020-03-05 Impact factor: 4.132
Authors: Cassandra M Wilkinson; Aristeidis H Katsanos; Noam H Sander; Tiffany F C Kung; Frederick Colbourne; Ashkan Shoamanesh Journal: PLoS One Date: 2022-10-18 Impact factor: 3.752
Authors: Annunziata Nusca; Michele Mattia Viscusi; Francesco Piccirillo; Aurelio De Filippis; Antonio Nenna; Cristiano Spadaccio; Francesco Nappi; Camilla Chello; Fabio Mangiacapra; Francesco Grigioni; Massimo Chello; Gian Paolo Ussia Journal: Life (Basel) Date: 2022-03-08